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Abstract:  50 
Background: IL-6, hsCRP and D-dimer levels are linked to adverse outcomes in HIV, but the 51 
strength of their associations with different clinical endpoints warrants investigation.  52 
Methods: Participants receiving standard of care in 2 HIV trials with measured biomarkers were 53 
followed to ascertain all-cause death, non-AIDS death, AIDS, cardiovascular disease (CVD) and 54 
non-AIDS-defining malignancies. HRs (95% CIs) of each endpoint for quartiles and log2-55 
transformed IL-6, hsCRP and D-dimer were calculated using Cox models. Marginal models 56 
modelling multiple events tested for equal effects of biomarkers on different endpoints.   57 
Results: Among 4304 participants, there were 157 all-cause deaths, 117 non-AIDS deaths, 101 58 
AIDS, 121 CVD and 99 non-AIDS-defining malignancies.  IL-6 was more strongly associated with 59 
most endpoints than hsCRP. IL-6 appeared to be a stronger predictor for CVD and non-AIDS-60 
defining malignancies than D-dimer but CIs overlapped. Independent associations of IL-6 were 61 
stronger for non-AIDS death (1.71; 1.43-2.04) and all-cause death (1.56; 1.33-1.84), and similar for 62 
CVD (1.35; 1.12-1.62) and non-AIDS-defining malignancies (1.30; 1.06-1.61). There was 63 
heterogeneity of IL-6 as a predictor for different endpoints (p<0.001), but not hsCRP (p=0.15) or D-64 
dimer (p=0.20). 65 
Conclusions: IL-6 is a stronger predictor of fatal events than CVD and non-AIDS-defining 66 
malignancies. Adjuvant anti-inflammatory and anti-thrombotic therapies should be tested in HIV. 67 
 68 
Keywords: HIV; coagulation; inflammation; IL-6; hsCRP; D-dimer; cardiovascular disease; 69 
cancer; AIDS 70 
 71 
 72 
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 74 
Text: 75 
Introduction: 76 
    Activated inflammation and hypercoagulation have consistently been linked to many adverse 77 
clinical outcomes during HIV infection, including progression to AIDS [1,2], anaemia [3], cancer 78 
[4], cardiovascular disease [5,6], diabetes [7] and all-cause mortality [8-10]. This observation is 79 
drawn from several studies that reported independent associations between raised plasma levels of 80 
inflammatory and coagulation biomarkers and subsequent risk of clinical outcomes [11]. In the 81 
Strategies for Management of Anti-Retroviral Therapy (SMART) trial, episodic antiretroviral 82 
therapy (ART) use increased all-cause mortality compared with continuous ART; the majority of 83 
the deaths being attributable to cardiovascular disease and cancer [12]. Out of a panel of six 84 
biomarkers tested in SMART participants at study entry, elevated levels of three biomarkers were 85 
independently and strongly associated with a subsequent risk of death during follow-up [8]: 1) 86 
interleukin-6 (IL-6), a pro-inflammatory cytokine that is a proximal mediator or upstream 87 
inflammatory marker [13]; 2)  high-sensitivity C-reactive protein (hsCRP), a downstream acute 88 
phase reactant whose hepatic production is stimulated, among other factors, by IL-6 [14]; and 3) D-89 
dimer, a degradation product of cross-linked intravascular fibrin that is a marker of 90 
hypercoagulation [15].  91 
     Many previous studies on IL-6, hsCRP and D-dimer have investigated associations with all-92 
cause death and different diseases in the setting of HIV infection [11], but the strength of 93 
associations these biomarkers have with different types of clinical endpoints is not well understood. 94 
For instance, it remains to be determined which biomarker best predicts AIDS-defining and non-95 
AIDS-defining morbidity among HIV+ persons receiving standard-of-care [16]. This poses an 96 
important research question as to whether activated inflammation and hypercoagulation contribute 97 
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in a general way to the development of multiple diseases or are instead more strongly associated 98 
with the development of specific pathologies [17].  Here, we set out to evaluate the relative value of 99 
IL-6, hsCRP and D-dimer as predictors of different clinical endpoints in a large cohort of HIV+ 100 
persons.  101 
     102 
Material and Methods: 103 
 104 
Study population: 105 
    This cohort study combined the control arms of two international HIV trials conducted by the 106 
International Network for Strategic Initiatives in Global HIV Trials: the SMART study 107 
(NCT00027352) [12] and the Evaluation of Subcutaneous Proleukin® in a Randomized 108 
International Trial (ESPRIT) (NCT00004978) [18]. Participants who had consented to storing blood 109 
for future research and whose plasma levels of IL-6, hsCRP and D-dimer were measured at study 110 
entry prior to randomization were included (N= 4,304). All participants in the control arms received 111 
standard of care according to HIV guidelines and were to be continuously maintained on ART. 112 
Prior to the enrolment of participants in the SMART and ESPRIT trials,  the institutional review 113 
board at each site had approved the original study protocols, and written informed consent was 114 
obtained from all participants. SMART and ESPRIT were conducted in compliance with the 115 
Declaration of Helsinki Guidelines, were registered on clinical trials databases and reviewed by 116 
independent data and safety interim monitoring boards. 117 
 118 
 119 
Biomarker measurements:  120 
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    For SMART participants, biomarkers were measured at the Laboratory for Clinical Biochemistry 121 
Research at the University of Vermont (Burlington). In the ESPRIT trial, laboratory measurements 122 
were performed by SAIC-Frederick (Frederick, MD). IL-6 was measured by the same method at 123 
each laboratory (Chemiluminescent Sandwich enzyme-linked immunosorbent assay [ELISA], R&D 124 
Sytems). hsCRP levels were determined by means of highly sensitive ELISA by both laboratories. 125 
For SMART participants, a NBTMII nephelometer, N Antiserum to Human CRP (Siemens 126 
Diagnostics) was used. For ESPRIT, an R&D Systems ELISA assay was used. D-dimer levels were 127 
determined by ELISA on the Sta-R analyzer, Liatest D-DI (Diagnostic Stago) for SMART 128 
participants and on a VIDAS instrument (BioMerieux Inc., Durham, North Carolina, USA) for 129 
ESPRIT participants.  As described in detail elsewhere [6,19], the assays for hsCRP and D-dimer, 130 
while different, compared well and measurements on duplicate samples were well correlated.  131 
 132 
Follow up and endpoints ascertainment: 133 
    Patients were followed from study entry until the first endpoint of interest, death, loss to follow-134 
up, or the closing date of each study, whichever occurred first. The following clinical endpoints 135 
were considered: 1) all-cause mortality, 2) non-AIDS and non-violent/accidental death, 3) fatal and 136 
non-fatal progression to AIDS (CDC category C events), 4) fatal and non-fatal cardiovascular 137 
disease (defined as myocardial infarction, stroke or coronary artery disease requiring a surgical 138 
procedure) and 5) fatal and non-fatal non-AIDS-defining malignancies (excluding basal and 139 
squamous cell skin cancers). All clinical endpoints were systematically reported to and centrally 140 
adjudicated by an endpoint review committee using pre-specified criteria [20]. Causes of death were 141 
determined using CoDe [21]. Clinical assessment intervals and total follow-up time varied by study. 142 
Median follow-up time was 29 months in SMART and 81 months in ESPRIT; overall, median 143 
follow-up was 48 months for the entire cohort. 144 
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 145 
 146 
Statistical analyses:  147 
    Hazard ratios (HR) with 95% confidence interval (CI) of each study endpoint for IL-6, hsCRP 148 
and D-dimer levels, modelled as log2-transformed values (i.e., per 2 fold higher), were calculated 149 
and used to compare the association of plasma levels of each biomarker with the risk of developing 150 
different clinical endpoints. Models for each biomarker were stratified by study to account for 151 
differences in underlying risk for the different cohorts.  This stratification also grouped participants 152 
by the two laboratories that measured biomarkers. We used sequential adjustment to fit three Cox 153 
proportional hazards regression models [models (1) – (3)], for each of the five clinical endpoints, 154 
and we repeated these three models for all three biomarkers. The Cox proportional hazards models 155 
were fit as follows: model (1) univariable; model (2) adjusted for demographics (age, sex, race and 156 
body mass index), nadir and baseline CD4+ cell count, baseline ART use and baseline HIV RNA, 157 
prior AIDS and cardiovascular disease, diabetes mellitus and hepatitis B virus/hepatitis C virus 158 
(HBV/HCV) co-infection; model (3) adjusted as in model (2) with further adjustment which 159 
included fitting biomarkers of inflammation and coagulation simultaneously. However, we did not 160 
include both biomarkers of inflammation in the same model because IL-6 and hsCRP have 161 
biological redundancy. The hepatic production of hsCRP is determined by IL-6 [14]. Therefore, 162 
elevated plasma levels of both biomarkers could have indicated similar pathophysiological 163 
processes.   164 
    We computed crude incidence rates and HRs (95% CIs) of clinical endpoints for each quartile of 165 
biomarker levels. To control for any differences in biomarker distributions among studies and inter 166 
laboratory variability, quartiles were defined separately for participants in SMART and ESPRIT. 167 
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    To compare the strength of associations of IL-6, hsCRP and D-dimer with each endpoint 168 
investigated, competing risk or marginal Cox model described by Wei, Lin & Weissfeld [22] were 169 
used to model multiple unordered events and to test for equal effects of biomarkers on different 170 
types of endpoints. With this approach, the fit of a model which assumed a common association for 171 
biomarkers with each endpoint was compared with the fit of a model that allowed the association to 172 
vary. The corresponding p-value is the probability that the magnitude of differences in estimated 173 
HRs for the endpoints could have arisen by chance if there were no real differences in the actual 174 
HRs. We also evaluated the strength of associations of each biomarker with specific endpoints by 175 
estimating the HRs of the highest vs. lowest biomarker quartiles and the HRs per 2-fold higher 176 
biomarker levels 177 
 178 
Secondary analyses 179 
    To test the robustness of our main findings and adjust for other biologically plausible 180 
confounders, we carried out two pre-planned secondary analyses. First, we recalculated HRs of 181 
clinical endpoints for quartiles of biomarker levels excluding events in the first two years of follow-182 
up. This analysis was aimed at addressing the possibility of bias by reverse causality. Because 183 
cardiovascular disease and cancer may have a long subclinical period prior to diagnosis, there is a 184 
possibility that elevated biomarkers levels were a consequence of the disease outcome instead of 185 
vice versa. Second, among SMART participants for whom information on smoking at the entry was 186 
collected, analyses further adjusting for smoking were carried out because smoking is causally 187 
related to cancer and cardiovascular disease.  188 
 189 
Results: 190 
 191 
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    There were approximately 19,000 person-years of follow-up [PYFU] among 4,304 participants 192 
(median age 42 years, median baseline CD4+ cell count 526/mm3, 77% men), including 157 all-193 
cause deaths (crude incidence rate [IR] 8.25/1,000 PYFU, 95% CI 6.96-9.53), 117 non-violent, non-194 
accidental and non-AIDS related deaths (6.14, 5.03-7.25), 101 progressions to AIDS (70 195 
opportunist infections and 32 AIDS-defining cancers; one participant in ESPRIT had both types of 196 
AIDS events) (5.39, 4.34-6.44), 121 cardiovascular disease events (6.47, 5.32-7.62) and 99 non-197 
AIDS-defining malignancies (5.27, 4.23-6.30). 198 
    Baseline characteristics are presented for both the entire cohort and separately for people who 199 
experienced the different clinical endpoints and are shown in Table 1. Levels of IL-6, hsCRP and 200 
D-dimer at study entry were higher among participants experiencing each clinical endpoint when 201 
compared to the entire cohort (Table 1). Crude incidence rates of all clinical endpoints increased 202 
across higher quartiles of all biomarkers (Figure 1). This was particularly true for IL-6 and D-dimer 203 
quartiles where a clearly graded response pattern was observed. 204 
    When compared to hsCRP, IL-6 was more strongly associated with most outcomes investigated 205 
both in univariable and multivariable models that considered log2-transformed biomarkers. IL-6 was 206 
a stronger predictor for cardiovascular disease events and non-AIDS-defining malignancies than D-207 
dimer (Figure 2, Table 2 and supplemental table 1) but confidence intervals overlapped.      208 
    Independent associations between log2 IL-6 and clinical endpoints were strongest for fatal events 209 
and similar for fatal and non-fatal cardiovascular disease and non-AIDS-defining malignancies in 210 
multivariable analyses. For instance, adjusted HRs (95% CI) calculated using model 3 were 211 
numerically higher for non-AIDS and non-violent/accidental death (1.71 [1.43-2.04] per 2 fold 212 
higher IL-6 level) and for all-cause death (1.56; 1.33-1.84) than for fatal or non-fatal cardiovascular 213 
disease events (1.35; 1.12-1.62) and non-AIDS-defining malignancies (1.30; 1.06-1.61) (Figure 2 214 
and supplemental table 1). The Wei-Lin-Weissfeld test found evidence of heterogeneity in 215 
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the association of log2 IL-6 with different endpoints (p<0.001), but not of log2 hsCRP (p=0.15) or 216 
log2 D-dimer (p=0.20). 217 
    In multivariable analyses comparing the highest to the lowest biomarker quartiles (Table 2, 218 
Figure 3 and Supplemental Table 2), HRs for all-cause death were similar for IL-6, hsCRP and D-219 
dimer. However, higher quartiles of IL-6 were independently associated with steeper risk gradients 220 
for all other outcomes than hsCRP. When compared to D-dimer, IL-6 appeared to be associated 221 
with steeper risk gradients for cardiovascular disease and non-AIDS-defining malignancies (Table 222 
2, Figure 3) but confidence intervals overlapped (Figure 3 and supplemental Table 2). The strength 223 
of associations of IL-6 and D-dimer with the other endpoints was similar (Table 2). 224 
 225 
Secondary analyses 226 
    After censoring the events occurring in the first two years of follow-up, confidence intervals of 227 
hazard ratios became larger owing to the smaller number of clinical endpoints (supplemental Table 228 
3). As a result, some associations between biomarker quartiles and certain types of clinical 229 
endpoints were no longer significant. This was the case, for instance, for the association between 230 
higher D-dimer quartiles and increased risk of progression to AIDS. However, most associations 231 
followed the same direction of and were broadly consistent with the main analyses including all 232 
follow-up (supplemental Table 2).  233 
    In SMART, adjustment for smoking weakened the association between higher quartiles of IL-6 234 
and death endpoints, but strengthened associations between higher quartiles of IL-6 and increased 235 
risk of cardiovascular disease and non-AIDS-defining malignancies (supplemental Table 4).  236 
 237 
Discussion: 238 
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    In a large cohort of HIV+ persons, we confirmed that activated inflammation and coagulation, as 239 
demonstrated by elevated levels of IL-6, hsCRP and D-Dimer, respectively, are linked to a variety 240 
of clinical endpoints representative of AIDS-associated and non-AIDS-associated morbidity. These 241 
three biomarkers are of particular interest because they have similarly been linked to disease in the 242 
general population. We found that the pathophysiological pathways that involve raised plasma 243 
levels of IL-6, hsCRP and D-dimer seem to be associated with different types of clinical endpoints. 244 
Higher IL-6 levels at study entry were more strongly associated with subsequent risk of non-AIDS-245 
defining endpoints such as cardiovascular disease and non-AIDS-defining malignancies than hsCRP 246 
or D-dimer. Furthermore, higher IL-6 was more strongly associated with fatal events than with fatal 247 
and non-fatal cardiovascular disease or non-AIDS-defining malignancies. These findings were 248 
broadly consistent after adjustment for confounders and accounting for potential reverse causality.  249 
    We demonstrated that IL-6 was superior to hsCRP to predict cardiovascular and non-AIDS-250 
defining malignancies. Gene-association studies using principles of Mendelian randomisation 251 
support a causal role of IL-6 in cardiovascular disease [23] and cancer [24]. With respect to hsCRP, 252 
polymorphisms in genes that are associated with higher levels of hsCRP were not associated with 253 
increased risk of cardiovascular disease [25,26] or cancer [27]. hsCRP seems, therefore, to be more 254 
of a epiphenom of underlying pathophysiological processes than a biomarker causally linked to 255 
adverse endpoints. However, some studies in the general population have found hsCRP to be more 256 
strongly associated with cardiovascular disease than IL-6 after adjustment for confounders [28,29]. 257 
The reasons why hsCRP is a less informative biomarker than IL-6 in the setting of HIV infection 258 
are unclear. Since hsCRP is a terminal product of the inflammatory cascade produced by the liver, 259 
subclinical hepatic impairment determined by conditions that may affect HIV+ persons 260 
disproportionally, such as HCV/HBV co-infection or hepatic steatosis, could  play a role [30,31].     261 
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    In this study, IL-6 was more strongly associated with cardiovascular disease and non-AIDS-262 
defining malignancies than D-dimer. There is paucity of data on the relative associations of IL-6 263 
and D-dimer with non-AIDS-defining outcomes during HIV infection. A previous report including 264 
SMART and ESPRIT participants who were receiving ART and virologically suppressed at 265 
baseline found that both IL-6 and D-dimer independently predicted the risk of a composite endpoint 266 
of serious non-AIDS morbidity or all-cause death [10]. Higher D-dimer levels also predicted a 267 
composite endpoint of non-AIDS-defining conditions in a case-control study involving HIV+ 268 
persons participating in ACTG trials [32]. In other reports involving the general population and 269 
HIV+ persons, D-dimer was found to predict cardiovascular disease [33,34] and cancer mortality 270 
[35]. 271 
    We also observed that elevated levels of IL-6 and D-dimer were similarly linked to increased risk 272 
of progression to AIDS. Elevated D-dimer levels had been previously associated with increased risk 273 
of AIDS or death among participants in Flexible Initial Retrovirus Suppression Therapies (FIRST) 274 
trial with advanced HIV infection (median CD4+ cell count of 163 cells/mm3) [2]. In a nested case-275 
control study involving participants from both arms in the SMART study; i.e. those randomized to 276 
continuous use of ART and to CD4+ cell count-guided ART interruptions, D-dimer was not 277 
associated with the development of opportunistic disease [1]. However, there appeared to be a 278 
stronger association between D-dimer and opportunistic disease among those receiving ART 279 
continually, although this is an underpowered analysis given the low number of events [1]. The 280 
prognostic value of D-dimer in HIV+ persons, particularly its relationship with AIDS-defining and 281 
non-AIDS-defining endpoints, deserves, therefore, further investigation. 282 
    Activated innate immunity seems to be a stronger determinant of IL-6 and D-dimer levels than 283 
adaptive immunity [32,36,37] but higher levels of each biomarker are related to different 284 
phenotypes of monocyte activation [36]. Furthermore, we had previously demonstrated that 285 
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different host factors and HIV-specific variables are associated with levels of IL-6 [38] and D-dimer 286 
[19].  This is compatible with the hypothesis that circulating levels of IL-6 and D-dimer reflect two 287 
distinct pathophysiological processes that may lead to different clinical endpoints. Indeed, 288 
combined scores of IL-6 and D-dimer have proven more helpful to estimate future risk of non-289 
AIDS-related morbidity than each biomarker individually [10].  290 
    The Wei-Lin-Weissfeld test indicated that higher IL-6 levels were more strongly associated with 291 
death endpoints than cardiovascular disease and cancer in our study. From our studies, higher levels 292 
of IL-6 at study entry were associated with greater risk of fatal cardiovascular disease and greater 293 
risk of death after a nonfatal cardiovascular event [6]. As for non-AIDS-defining malignancies, we 294 
also found that the risk associated with elevated plasma levels of IL-6 was higher for fatal than for 295 
non-fatal events among HIV+ persons (unpublished data). Furthermore, raised inflammatory 296 
biomarkers were more strongly associated with cancer death than with non-fatal cancer in healthy 297 
elderly individuals [39] and with shorter survival following cancer diagnosis [40]. Taken together, 298 
these findings suggest that higher IL-6 is not only a marker of disease risk, but also of disease 299 
severity. 300 
    Our study had several limitations. First, we only studied three biomarkers. Other biomarkers not 301 
tested might have provided useful information. Second, we studied IL-6, hsCRP and D-dimer at 302 
study entry only because follow-up biomarkers were only available in a subset of participants; 303 
therefore, it was not possible to investigate the effects of changes in plasma levels of these 304 
biomarkers over time. The fact that biomarker levels may have changed over time during follow-up 305 
means that the association between these biomarkers and the clinical endpoints could be greater 306 
than those observed. Third, associations of each biomarker were investigated for several clinical 307 
endpoints. This means that false positive results may have arisen from multiple testing.  Fourth, the 308 
strong and independent associations between raised biomarker levels and clinical endpoints 309 
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observed in this large cohort of HIV+ persons do not necessarily mean that these biomarkers are 310 
valuable for risk stratification of individual patients [41]. 311 
    No study has thus far provided irrefutable evidence for a causal relationship between activated 312 
inflammation/coagulation and clinical events during HIV infection. Among HIV+ persons with 313 
early HIV infection enrolled in the Strategic Timing of AntiRetroviral Treatment (START) trial, 314 
immediate ART reduced incidence of AIDS-defining events and cancer compared to treatment 315 
deferral until CD4+ counts dropped below 350 cells/mm3[42]. Because ART decreases 316 
inflammation and coagulation by suppressing HIV replication [16,43,44], START findings are 317 
consistent with the hypothesis of activated inflammation and coagulation as a contributing cause of 318 
morbidity, although the benefits of immediate ART may also have been mediated by other 319 
mechanisms. The Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease 320 
in HIV-Infected Adults (REPRIEVE) trial will randomise 6,500 HIV+ individuals with low to 321 
moderate cardiovascular risk receiving ART to start statin or placebo. In the Justification for the 322 
Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER), 323 
which recruited HIV-uninfected individuals with elevated hsCRP levels at baseline, statins were 324 
found to reduce risk of cardiovascular disease by 50% [45]. However, because REPRIEVE and 325 
JUPITER have cardiovascular disease as the main study endpoint, it is impossible to determine 326 
whether the clinical benefit of statin therapy is mediated by a reduction cholesterol, a reduction of 327 
inflammation or a combination of both [17,46]. Three additional placebo-controlled trials of anti-328 
inflammatory therapies to reduce risk of cardiovascular events started enrolling participants:  the 329 
Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS), which is assessing a 330 
monoclonal antibody against interleukin-1β [47]; the Cardiovascular Inflammation Reduction Trial 331 
(CIRT), which is assessing low dose methotrexate among HIV-uninfected persons [48], and the 332 
NCT01949116 trial, which is assessing  methotrexate  among HIV+ persons. By deploying 333 
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therapies that directly target inflammation, these trials will be important to test the inflammatory 334 
hypothesis of cardiovascular disease. However, their results will not address the question as to 335 
whether enhanced inflammation and coagulation is causally linked to cancer and other non-AIDS-336 
defining morbidities.      337 
        To conclude, IL-6 is a stronger predictor of fatal events than fatal and non-fatal cardiovascular 338 
disease and non-AIDS-defining cancer. There is a need for clinical endpoint-driven trials to 339 
determine whether anti-thrombotic and anti-inflammatory therapies to lower levels of IL-6, hsCRP 340 
and D-dimer can reduce morbidity and mortality in treated HIV infection. Such trials would not 341 
only determine the potential role of adjuvant anti-inflammatory and anti-thrombotic therapies in the 342 
management of HIV infection, but also elucidate whether enhanced inflammation and coagulation 343 
are causally linked to the development of AIDS-defining and non-AIDS-defining morbidity.  344 
 345 
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Table 1: 
Baseline characteristics 
Participants in the control arms of the SMART and ESPRIT trials 
Baseline 
Characteristics 
N (%) or Median 
[IQR] 
All participants 
N= 4,304 
All-cause deaths 
N=157 
non-AIDS and 
non-violent/ 
accidental deaths 
N=117 
AIDS 
N=101 
CVD 
N=121 
non-AIDS-
defining 
malignancies 
N=99 
Age (years) 42 [36 , 49] 48 [40 , 54] 48 [41 , 55] 44 [38 , 50] 49 [43 , 56] 50 [44 , 57] 
Female sex 1,002 (23.3) 28 (17.8) 17 (14.5) 22 (21.8) 14 (11.6) 14 (14.1) 
Black Race 907 (21.1) 29 (18.5) 25 (21.4) 18 (17.8) 26 (21.5) 26 (26.3) 
BMI (kg/m2) 24.4 [22.1 , 27.1] 23.5 [21.4 , 27.3] 23.3 [21.3 , 27.1] 25.2 [22.6 , 29.0] 24.0 [22.1 , 27.4] 23.9 [21.7 , 25.8] 
Prior AIDS 1,093 (25.4) 46 (29.3) 32 (27.4) 42 (41.6) 47 (38.8) 21 (21.2) 
Hepatitis B/C 761 (17.7) 54 (34.4) 41 (35.0) 16 (15.8) 18 (14.9) 27 (27.3) 
Prior CVD 112 (2.6) 14 (9.0) 12 (10.3) 1 (1.0) 16 (13.3) 5 (5.1) 
Diabetes 217 (5.1) 14 (9.0) 10 (8.6) 7 (6.9) 14 (11.7) 9 (9.1) 
PI based ART 1,478 (34.3) 53 (33.8) 45 (38.5) 31 (30.7) 52 (43.0) 41 (41.4) 
NNRTI based ART 1,643 (38.2) 52 (33.1) 39 (33.3) 34 (33.7) 30 (24.8) 30 (30.3) 
CD4 (cells/mm3) 526 [415 , 701] 451 [370 , 594] 470 [384 , 639] 466 [376 , 599] 515 [401 , 673] 526 [404 , 679] 
CD4 Nadir 
(cells/mm3) 
230 [120 , 337] 194 [93 , 297] 194 [85 , 282] 190 [90 , 298] 187 [74 , 301] 219 [97 , 311] 
HIV RNA ≤500 
copies/mL) 
3,263 (75.8) 97 (61.8) 77 (65.8) 51 (50.5) 88 (72.7) 75 (75.8) 
IL-6 (pg/mL) 1.80 [1.18 , 2.90] 3.09 [2.10 , 4.40] 3.17 [2.10 , 4.49] 2.42 [1.40 , 3.33] 2.60 [1.78 , 4.30] 2.50 [1.81 , 3.58] 
hsCRP (μg/mL) 1.60 [0.69 , 3.67] 2.83 [1.53 , 6.27] 2.70 [1.57 , 6.18] 2.03 [0.83 , 4.50] 2.33 [1.02 , 5.05] 2.54 [1.13 , 4.93] 
D-dimer (μg/mL) 0.24 [0.15 , 0.38] 0.33 [0.23 , 0.55] 0.35 [0.23 , 0.55] 0.31 [0.22 , 0.53] 0.31 [0.20 , 0.51] 0.28 [0.18 , 0.52] 
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Table 2:  
Hazard ratios a (95% CIs) of study endpoints for plasma levels of IL-6, hsCRP and D-dimer.  
 IL-6 
 
hsCRP D-dimer 
Study 
Endpoint 
2 fold 
higher level 
4th/1st 
quartile 
2 fold 
higher level 
4th/1st 
quartile 
2 fold 
higher level 
4th/1st 
quartile 
All-cause 
deaths 
1.64  
(1.41-1.92)  
3.07  
(1.70-5.55) 
1.29  
(1.17-1.42) 
2.73  
(1.56-4.69) 
1.32  
(1.14-1.52)  
3.00  
(1.61-5.59) 
Non-AIDS and 
non-violent/ 
accidental 
deaths 
1.77  
(1.50-2.10)  
6.31  
(2.68-
14.83) 
1.30  
(1.16-1.46) 
3.10  
(1.59-6.05) 
1.30  
(1.10-1.53)  
3.38  
(1.62-7.08) 
Progression to 
AIDS 
1.32  
(1.07-1.62)  
1.63  
(0.83-3.21) 
1.07  
(0.94-1.21) 
1.35  
(0.74-2.48) 
1.35  
(1.12-1.63)  
2.20  
(1.07-4.50) 
Cardiovascular 
disease events 
1.40  
(1.17-1.67)  
3.34  
(1.66-6.70) 
1.11  
(0.99-1.24) 
1.89  
(0.99-3.63) 
1.22  
(1.04-1.43)  
1.80  
(0.98-3.29) 
Non-AIDS-
defining 
malignancies 
1.31  
(1.07-1.61)  
3.12  
(1.42-6.84) 
1.16  
(1.02-1.32) 
1.68  
(0.86-3.28) 
1.09  
(0.91-1.31)  
1.03  
(0.55-1.94) 
a Hazards ratios adjusted for demographics (age, sex, race and BMI),  nadir and baseline CD4+ cell 
count, ART use  and baseline HIV RNA, prior AIDS and cardiovascular disease, diabetes mellitus and 
HBV/HCV co-infection, stratified by study (model 2). For detailed information on results using models 
1 and 3, refer to supplemental Table 1 and supplemental Table 2.  
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Figures legends: 
 
 
Figure 1: Crude incidence rates of clinical endpoints across biomarker quartiles. Quartile cut-points 
were defined differently for each study as described in the supplemental Table 2. NADM: non-
AIDS-defining malignancies  
 
 
Figure 2: HRs (95% CI) for clinical endpoints associated with baseline biomarkers. NADM: non-
AIDS-defining malignancies 
Model 1: unadjusted associations, stratified by study 
Model 2: adjusted for demographics (age, sex, race and BMI), ART use, nadir and baseline CD4+ 
cell count, baseline HIV RNA, prior AIDS and cardiovascular disease, diabetes mellitus and 
HBV/HCV co-infection, stratified by study 
Model 3: HRs for IL-6 and D-dimer using models (2)  and including both biomarkers 
simultaneously and HRs for hsCRP using model (2) also adjusted for D-dimer, stratified by study 
 
 
Figure 3: Adjusted HRs* (95% CI) for clinical endpoints associated with biomarker quartiles. 
NADM: non-AIDS-defining malignancies Quartile cut-points were defined differently for each 
study as described in the supplemental Table 2 *HRs adjusted for factors included in model 2; 
namely demographics (age, sex, race and BMI), ART use, nadir and baseline CD4+ cell count, 
baseline HIV RNA, prior AIDS and cardiovascular disease, diabetes mellitus and HBV/HCV co-
infection. HRs calculated as in models (1) and (3) showed consistent results (data not shown) 
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